Integrated proteomic and genomic analysis to identify predictive biomarkers for valproate response in bipolar disorder: a 6-month follow-up study

Hyunju Lee,Dohyun Han,Kyung Sue Hong,Kyooseob Ha,Hyeyoon Kim,Eun Young Cho,Woojae Myung,Sang Jin Rhee,Jayoun Kim,Tae Hyon Ha,Kang Eun Lee,Hye Won Jung,Yejin Lee,Dongbin Lee,Hyeona Yu,Daseul Lee,Yun Seong Park,Yong Min Ahn,Ji Hyun Baek,Se Hyun Kim
DOI: https://doi.org/10.1186/s40345-024-00342-x
2024-05-18
International Journal of Bipolar Disorders
Abstract:Several genetic studies have been undertaken to elucidate the intricate interplay between genetics and drug responses in bipolar disorder (BD). However, there has been notably limited research on biomarkers specifically linked to valproate, with only a few studies investigating integrated proteomic and genomic factors in response to valproate treatment. Therefore, this study aimed to identify biological markers for the therapeutic response to valproate treatment in BD. Patients with BD in remission were assessed only at baseline, whereas those experiencing acute mood episodes were evaluated at three points (baseline, 8 ± 2 weeks, and 6 ± 1 months). The response to valproate treatment was measured using the Alda scale, with individuals scoring an Alda A score ≥ 5 categorized into the acute-valproate responder (acute-VPAR) group. We analyzed 158 peptides (92 proteins) from peripheral blood samples using multiple reaction monitoring mass spectrometry, and proteomic result-guided candidate gene association analyses, with 1,627 single nucleotide variants (SNVs), were performed using the Korean chip.
psychiatry
What problem does this paper attempt to address?